Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.79 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.79 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685168 | 1.00 | ITGB3 (0.79) | ITGB3ITGA2BPTPN1ITGB1ITGA4 | |
| SCHEMBL7335757 | 0.96 | ITGB3 (0.74) | ITGB3ITGA2BPTPN1ITGB1ITGA4 | |
| SCHEMBL7330647 | 0.96 | ITGB3 (0.74) | ITGB3ITGA2BPTPN1ITGB1ITGA4 | |
| SCHEMBL18764418 | 0.92 | ITGB3 (0.78) | ITGB3ITGA2BPTPN1ITGA4ACE | |
| SCHEMBL23302994 | 0.91 | ITGB3 (0.76) | ITGB3ITGA2BPTPN1ACEHDAC8 | |
| SCHEMBL23302993 | 0.91 | ITGB3 (0.76) | ITGB3ITGA2BPTPN1ACEHDAC8 | |
| SCHEMBL7300335 | 0.91 | ITGB3 (0.76) | ITGB3ITGA2BPTPN1ACEHDAC8 | |
| SCHEMBL3713178 | 0.90 | ITGB3 (0.71) | ITGB3ITGA2BPTPN1ITGB1ITGA4 | |
| SCHEMBL3188805 | 0.90 | ITGB3 (0.71) | ITGB3ITGA2BPTPN1ITGB1ITGA4 | |
| SCHEMBL1000744 | 0.90 | ITGB3 (0.71) | ITGB3ITGA2BPTPN1ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| CN-107021943-B | 7-epi-baccatin III derivatives, and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-12-29 | — | — | CN | disclosed |
| US-9266853-B2 | Orally available viridiofungin derivative possessing anti-HCV activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2886530-A1 | ORALLY ADMINISTRABLE VIRIDIOFUNGIN DERIVATIVE HAVING ANTI-HCV ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-06-24 | — | — | EP | disclosed |
| US-8183383-B2 | Protein tyrosine phosphatase 1B inhibitor, preparation methods and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-22 | — | — | US | disclosed |
| US-20100197927-A1 | Protein Tyrosine Phosphatase 1B Inhibitor, Preparation Methods and Uses Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2133342-A1 | PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR, PREPARATION METHODS AND USES THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210666-A1 | ORALLY AVAILABLE VIRIDIOFUNGIN DERIVATIVE POSSESSING ANTI-HCV ACTIVITY | ZC3HAV1, SLC10A1, CYP51A1 | ITGB3 2937/4885ITGA2B 3346/4885PTPN1 3001/4885 |
| US-20100197927-A1 | Protein Tyrosine Phosphatase 1B Inhibitor, Preparation Methods and Uses Thereof | PTPA, PTPN7, PTPN5 | ITGB3 4715/4885ITGA2B 3983/4885PTPN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.